



Pharmaceuticals Division: Overview Development Portfolio (as of November 8th, 2022)

Phase I (17)	Phase II (10)	Phase III (9)
Elimusertib (ATR Inhibitor) (BAY 1895344)	Regorafenib (combi Nivolumab) (BAY 734506) /// Solid tumors (recurrent or metastatic)	Darolutamide (AR Inhibitor) (BAY 1841788) /// Prostate Cancer (mHSPC) (ARANOTE) /// Prostate Cancer (aHSPC) (DASL-HiCaP)
SLFN12 Complex-Inducer (BAY 2666605)	Regorafenib (combi Pembrolizumab) (BAY 734506) /// Hepatocellular Carcinoma (HCC)	Copanisib (PI3K Inhibitor) (BAY 806946) /// Non-Hodgkin Lymphoma (CHRONOS-4)
mEGFR Inhibitor (BAY 2927088)	Asundexian (FX1a Inhibitor) (BAY 2433334) /// Stroke Prevention in Atrial Fibrillation (PACIFIC-AF) /// 2 ^o Stroke Prevention (PACIFIC-STROKE) /// Major Adverse Cardiac Events Prevention (PACIFIC-AMI)	Finerenone (MR Antagonist) (BAY 948862) /// Heart Failure (HFmr/pEF) (FINEARTS-HF) /// Non-diabetic CKD (FIND-CKD)
HER2-TTC (HER2-Targeted Thorium Conjugate) (BAY 2701439)	Runcaciguat (sGC Activator) (BAY 1637108) /// Chronic Kidney Disease (CKD) (CONCORD) /// Non-prolif. Diabetic Retinopathy (NPDR) (NEON-NPDR)	Vericiguat (sGC Stimulator) (BAY1021189) /// Heart Failure (HFref) (VICTOR*)
Bapoptulimab (ILDR2 fb Antibody) (BAY 1905254)	Adrenomedullin Pegol (PEG-ADM) (BAY 1097761) /// Acute Resp. Distress Syn. (ARDS) (SEAL TRIAL)	Elinzanetant (Neurokinin-1,3 Rec Antagonist) (BAY 3427080) /// Vasomotor Symptoms (OASIS)
CCR8 Ab (BAY 3375968)	BDKRB1 Receptor Antagonist (BAY 2599210) /// Neuropathic Pain (BRADiNP)	Aflibercept 8MG (BAY 865321) /// Diabetic Macular Edema (DME) (PHOTON**) /// Neovasc. Age-rel. Macular Degen. (nAMD) (PULSAR)
AhR Inhibitor (BAY 3176803)	Gadoquatrane (High Relaxivity Contrast Agent) (BAY 1747846) /// Magnetic Resonance Imaging (HRCA-PAT)	
Congestive Heart Failure Gene Therapy (NAN-101)		
sGC Activator (BAY 3283142)		
P2X4 Antagonist (BAY 2328065)		
BDKRB1 Receptor Antagonist (BAY 2599210)		
Pompe Disease Gene Therapy (ACTUS-101)		
Parkinson's Disease Gene Therapy (AAV2_GDNF_PD)		
Parkinson's Disease Cell Therapy (DA-01)		
sGC Activator (BAY 1211163)		
ADRA2C Antagonist (BAY 2925976)		
Zabedoseritib (IRAK4 Inhibitor) (BAY 1834845)		

* Conducted by Merck & Co.

** Conducted by Regeneron Pharmaceuticals

Selection of major Pharma development portfolio projects in clinical Phase I to III

■ ONCOLOGY	■ WOMEN'S HEALTH
■ CARDIOVASCULAR DISEASES	■ OTHERS